Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram

Cancer

Volumn 116, Issue 16, 2010, Pages 3883-3891

  Donahue, Timothy R ^a   Kattan, Michael W ^b   Nelson, Scott D ^a,c   Tap, William D ^a,c   Eilber, Frederick R ^a,c   Eilber, Fritz C ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Histopathologic response; Neoadjuvant therapy; Retroperitoneal sarcoma; Sarcoma nomogram

Indexed keywords

ANDRIAMYCIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NECROSIS; NOMOGRAM; PRIORITY JOURNAL; RETROPERITONEAL SARCOMA; ADJUVANT CHEMOTHERAPY; COMPARATIVE STUDY; EVALUATION STUDY; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROPERITONEAL NEOPLASMS; SARCOMA; SURVIVAL;

ADOLESCENT; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NOMOGRAMS; RADIOTHERAPY, ADJUVANT; RETROPERITONEAL NEOPLASMS; SARCOMA; SURVIVAL ANALYSIS;

EID: 77956828821     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25271     Document Type: Article

References (55)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. DeVita VT, Hellman S, Rosenberg SA. Cancer, Principles & Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
3. Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228:355-365.
4. Cody HS III, Turnbull AD, Fortner JG, et al. The continuing challenge of retroperitoneal sarcomas. Cancer. 1981;47:2147-2152.
5. Singer S, Corson JM, Demetri GD, et al. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg. 1995;221:185-195.
6. Alvarenga JC, Ball AB, Fisher C, et al. Limitations of surgery in the treatment of retroperitoneal sarcoma. Br J Surg. 1991;78:912-916.
7. Karakousis CP, Gerstenbluth R, Kontzoglou K, et al. Retroperitoneal sarcomas and their management. Arch Surg. 1995;130:1104-1109.
8. Catton CN, O'Sullivan B, Kotwall C, et al. Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 1994;29:1005-1010.
9. McGrath PC, Neifeld JP, Lawrence W Jr, et al. Improved survival following complete excision of retroperitoneal sarcomas. Ann Surg. 1984;200:200-204.
10. Raut CP, Pisters PW. Retroperitoneal sarcomas: combined-modality treatment approaches. J Surg Oncol. 2006;94:81-87.
11. Glenn J, Sindelar WF, Kinsella T, et al. Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum. Surgery. 1985;97:316-325.
12. Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19:3203-3209.
13. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-1230.
14. Picci P, Bohling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol. 1997;15:1553-1559.
15. Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol. 1993;11:1763-1769.
16. Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366-5372.
17. Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7:109-115; discussion 116-117.
18. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007;25:313-318.
19. Eilber FC, Kattan MW. Sarcoma nomogram: validation and a model to evaluate impact of therapy. J Am Coll Surg. 2007;205:S90-S95.
20. Solit DB, Morris M, Slovin S, et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer. 2003;98:1842-1848. (Pubitemid 37310226)
21. Yamamoto T, Ito K, Miyakubo M, et al. Nomogram ranking as new objective evaluation method in various treatment strategies for patients with prostate cancer with various clinicopathologic backgrounds. Urology. 2008;72:892-897.
22. White RR, Kattan MW, Haney JC, et al. Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. Ann Surg Oncol. 2006;13:1485-1492.
23. Dalal KM, Kattan MW, Antonescu CR, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244:381-391.
24. Kattan MW, Heller G, Brennan MF. A competing-risks nomogram for sarcoma-specific death following local recurrence. Stat Med. 2003;22:3515-3525.
25. Canter RJ, Qin LX, Maki RG, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14:8191-8197.
26. Wunder JS, Paulian G, Huvos AG, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am. 1998;80:1020-1033.
27. Huvos AG. Bone Tumors, Diagnosis, Treatment, and Prognosis. Philadelphia, PA: WB Saunders; 1979.
28. Hajdu SI, Shiu MH, Brennan MF. The role of the pathologist in the management of soft tissue sarcomas. World J Surg. 1988;12:326-331.
29. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20:791-796.
30. Eilber FC, Brennan MF, Eilber FR, et al. Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer. 2004;101:2270-2275.
31. Ghali WA, Quan H, Brant R, et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA. 2001;286:1494-1497.
32. Herman K, Kusy T. Retroperitoneal sarcoma - the continued challenge for surgery and oncology. Surg Oncol. 1998;7:77-81.
33. Dalton RR, Donohue JH, Mucha P Jr, et al. Management of retroperitoneal sarcomas. Surgery. 1989;106:725-732; discussion 732-733.
34. Hassan I, Park SZ, Donohue JH, et al. Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience. Ann Surg. 2004;239:244-250.
35. Jaques DP, Coit DG, Hajdu SI, et al. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg. 1990;212:51-59.
36. Kilkenny JW III, Bland KI, Copeland EM III. Retroperitoneal sarcoma: the University of Florida experience. J Am Coll Surg. 1996;182:329-339.
37. Heslin MJ, Lewis JJ, Nadler E, et al. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol. 1997;15:2832-2839.
38. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859-868.
39. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197-203.
40. Karakousis CP, Velez AF, Gerstenbluth R, et al. Resectability and survival in retroperitoneal sarcomas. Ann Surg Oncol. 1996;3:150-158.
41. Tepper JE, Suit HD, Wood WC, et al. Radiation therapy of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1984;10:825-830.
42. Gieschen HL, Spiro IJ, Suit HD, et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2001;50:127-131.
43. Sindelar WF, Kinsella TJ, Chen PW, et al. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. Arch Surg. 1993;128:402-410.
44. Jones JJ, Catton CN, O'Sullivan B, et al. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma. Ann Surg Oncol. 2002;9:346-354.
45. Petersen IA, Haddock MG, Donohue JH, et al. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2002;52:469-475.
46. Pisters PW, Ballo MT, Fenstermacher MJ, et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol. 2003;21:3092-3097.
47. Zlotecki RA, Katz TS, Morris CG, et al. Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma: the University of Florida experience. Am J Clin Oncol. 2005;28:310-316.
48. Pisters PW, O'Sullivan B. Retroperitoneal sarcomas: combined modality treatment approaches. Curr Opin Oncol. 2002;14:400-405.
49. Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer. 2005;103:402-408.
50. Eilber FC, Eilber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004;240:686-695; discussion 695-697.
51. Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007;246:105-113.
52. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694-701.
53. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005;103:339-348.
54. Evilevitch V, Weber WA, Tap WD, et al. Change in quantitative FDG-PET was significantly more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high grade soft tissue sarcomas. Clin Cancer Res. 2008;14:715-720.
55. Benz MR, Czernin J, Allen-Auerbach M, et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high grade soft tissue sarcomas. Clin Cancer Res. 2009;15:2856-2863.